Akcea

Akcea is a biopharmaceutical company that develops RNA-targeted antisense therapeutics for the treatment of cardiometabolic lipid disorders. Read more

30 Followers on Owler
30 Followers on Owler
30 Followers on Owler
30 Followers on Owler

Akcea

Akcea is a biopharmaceutical company that develops RNA-targeted antisense therapeutics for the treatment of cardiometabolic lipid disorders. Read more

Damien McDevitt's photo - CEO of Akcea

CEO

Damien McDevitt

CEO Approval Rating

75/100

AKCEA TOP COMPETITORS OR ALTERNATIVES

RANK

COMPANY

CEO

CEO RATING

EMPLOYEES

FUNDING

REVENUE

Missing a competitor? Contribute!

Alnylam is Akcea's #1 rival. Alnylam was founded in 2002 in Cambridge, Massachusetts. Like Akcea, Alnylam also operates in the Pharmaceuticals space. Alnylam generates $81.9M more revenue than Akcea.

Eidos is one of Akcea's top competitors. Eidos is headquartered in San Francisco, California, and was founded in 2013. Like Akcea, Eidos also works within the Biotechnology sector. Eidos generates 5.46% the revenue of Akcea.

Amryt Pharma is seen as one of Akcea's top competitors. Amryt Pharma was founded in 2015, and its headquarters is in London, England. Like Akcea, Amryt Pharma also works within the Biotechnology sector. Amryt Pharma has 112 fewer employees than Akcea.

Weigh-in!

Help the Owler community know more

Growth Score - 1/1

Is $489M a good estimate for Akcea's revenue?

Akcea Acquisitions

No recent acquisitions found related to Akcea

Akcea Funding History

Since Akcea was founded in 2015, it has participated in 2 rounds of funding. In total Akcea has raised $668.2M. Akcea's last funding round was on Jul 2017 for a total of $125.0M

ROUND

FUNDING DATE

AMOUNT

INVESTORS

IPO
Jul 2017
$125M
-
Equity
Dec 2015
$543.2M
-

Since Akcea was founded in 2015, it has participated in 2 rounds of funding. In total Akcea has raised $668.2M. Akcea's last funding round was on Jul 2017 for a total of $125.0M

Akcea Investments

No recent investments found related to Akcea

Akcea News

November 4, 2020The Pharma Letter

Ionis and Akcea set for $75 million milestone payment

Akcea and US pharma giant Pfizer today revealed the start of a Phase IIb study of vupanorsen, an anti... See more »
October 30, 2020Micro Small Cap

Ionis and Akcea win prestigious Prix Galien Award for TEGSEDI (inotersen) as Best Biotechnology Product

Ionis and Akcea win prestigious Prix Galien Award for TEGSEDI® (inotersen) as Best Biotechnology Prod... See more »
October 12, 2020Micro Small Cap

Ionis Pharmaceuticals completes acquisition of Akcea Therapeutics

IONIS-PHARMACEUTICALSIonis Pharmaceuticals completes acquisition of Akcea TherapeuticsTransaction cre... See more »
September 23, 2020Micro Small Cap

Monteverde & Associates Continues its Investigation into the Following Merger

NEW YORK, NY / ACCESSWIRE / September 23, 2020 / Juan Monteverde, founder and managing partner at Mon... See more »
September 18, 2020The Pharma Letter

Waylivra becomes first and only FCS therapy available on NHS England

Today Akcea Therapeutics announced that Waylivra (volanesorsen), the first and only for the ultra-rar... See more »
September 16, 2020The Business Journals: Boston

Akcea rejected $2.5B acquisition before Ionis' $500M bid

Akcea's decision to turn down one offer may have cost the company's investors upwards of $600 million... See more »
September 15, 2020San Diego Business Journal

Ionis Pharmaceuticals to Acquire Remaining Stake in Akcea

BIOTECH: Boston Co. Was Spun Out of Ionis, Had IPO in 2017... See more »

Akcea Press Releases

June 17, 2020centralcharts

Akcea Therapeutics to Present at the BMO 2020 Prescriptions for Success Healthcare Conference

Akcea Therapeutics to Present at the BMO 2020 Prescriptions for Success Healthcare Conference PR News... See more »
June 9, 2020PR Newswire

Akcea Appoints New Senior Vice President, Business Development and Corporate Strategy

BOSTON, June 9, 2020 /PRNewswire/ -- Akcea Therapeutics, Inc. (NASDAQ: AKCA), a majority-owned affili... See more »
May 18, 2020PR Newswire

Akcea Announces Appointment of New Chief Financial Officer

BOSTON, May 18, 2020 /PRNewswire/ -- Akcea Therapeutics, Inc. (NASDAQ: AKCA), a majority-owned affili... See more »
May 14, 2020PR Newswire

Akcea Announces Approval for Reimbursement of TEGSEDI (inotersen) in Spain for Treatment of Hereditary Transthyretin Amyloidosis with Polyneuropathy

BOSTON, May 14, 2020 /PRNewswire/ -- Akcea Therapeutics, Inc. (NASDAQ: AKCA), a majority-owned affili... See more »
May 5, 2020PR Newswire

Akcea Reports Financial Results and Highlights for First Quarter 2020

BOSTON, May 5, 2020 /PRNewswire/ -- Akcea Therapeutics, Inc. (NASDAQ: AKCA), a majority-owned affilia... See more »
April 29, 2020NewsFile

Nationally Ranked Shareholder Rights Firm Labaton Sucharow Announces Proprietary Investigation of Akcea Therapeutics, Inc. (AKCA)

New York, New York--(Newsfile Corp. - April 29, 2020) - Labaton Sucharow LLP, a leading and award win... See more »
April 10, 2020centralcharts

Investigation on Behalf of Akca Shareholders

Boston, Massachusetts--(Newsfile Corp. - April 10, 2020) - Thornton Law Firm LLP, a law firm that rep... See more »

Akcea Videos

Social Media

Akcea Headquarters

22 Boston Wharf Road 9th Floor

Boston, Massachusetts02210

617-207-0202

Driving Directions »

Trending Companies

Akcea Summary

ABOUT

Overview

Akcea is a biopharmaceutical company that develops RNA-targeted antisense therapeutics for the treatment of cardiometabolic lipid disorders. Akcea was founded in 2015. Akcea's headquarters is located in Boston, Massachusetts, USA 02210. It has raised ...

CEO

Akcea's CEO, Damien McDevitt, currently has an approval rating of 75%. Akcea's primary competitors are Alnylam, Eidos & Amryt Pharma.

Website

akceatx.com

Frequently Asked Questions about Akcea

  1. When was Akcea founded?

    Akcea was founded in 2015
  2. Who is Akcea's CEO?

    Akcea's CEO is Damien McDevitt
  3. How much revenue does Akcea generate?

    Akcea generates $489M in revenue
  4. How much funding does Akcea have?

    Akcea has historically raised $668.2M in funding
  1. Where is Akcea's headquarters?

    Akcea's headquarters is in Boston Massachusetts, USA
  2. How many employees does Akcea have?

    Akcea has 294 employees
  3. What sector does Akcea operate in?

    Akcea is in Biotechnology, Pharmaceuticals
  4. Who are Akcea's competitors?

    Akcea's top competitors are Alnylam, Eidos, Amryt Pharma